Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Buying all around that VWAP! Love it.
And up it is. Looks like the institutional boys are buying more WPRT.
Just hit VWAP in the five minute. Pop or drop from here.
Very well said.
I put a buddy of mine onto USRM several months ago. He is a buy and hold guy who doesn't worry about the day to day pps fluctuations. Talked to him yesterday for the first time in months and there was a stark contrast in viewpoint. Dude was happy and talking about how much money USRM had made him so far. Won't sell for anything he says. In his words, "This is one of those do or die deals. Hell no I'm not selling."
Some times you just have to step away for a day or two. Makes all the difference if your frustrated with the pps. But if you know what you own, and you are willing to be patient, USRM is going to pay up. My advice to all is to do what I do. Buy a little each week no matter what the price is.
This is about long term vision friends.
PPS Should be moving up from here.....we'll see
third day in a row to test this level......
Tax cuts being unveiled now, let's see how the markets react......
Unveiling the tax code now. Let's see how the markets react.....
STEM CELLS MAKE PEOPLE LAUGH!!!!!
http://www.kentucky.com/entertainment/performing-arts/article182095981.html
EVEN CHUCK NORRIS’ WIFE USES STEM CELLS!
http://www.dailymail.co.uk/health/article-5040757/Chuck-Norris-claims-MRI-scan-poisoned-wife.html
KICKING BIG PHARMA’S ASS!
FIRST PERSON CURED OF AIDS BY........STEM CELLS, YOU GUESSED IT.
http://www.wearecentralpa.com/news/only-person-cured-of-hiv-shares-his-story/849347055
You have no vision and no idea what you're commenting on. WPRT will be hitting 70-80 dollars a share in the years to come. NLG is the future of trucking, and in order to compete with the trucking industry the rails will be converting to NLG soon or later. You'll see. WPRT will see exponential growth over the next ten to twenty years.
That's awesome......support
12 Hunter! I stand corrected......Awesome!
Awesome post. You said USRM was the religion, the priests the other day. Looking at the size of their foot print as well as the things said in that article I would have to say you hit that on the head.....
Looked really good at start of day didn't it. Good news this morning though for us longs. The patient will win the day very soon. I was surprised about that foot print, put in a great deal of time with google and never could have known.
And that's how bricks bounce ......
And converting to LNG reduces a companies fuel cost by TWO THIRDS!!!! The trucking industry pays hundreds of millions of dollars in fuel cost. That is big.
Here's a reminder of some other things that are still in play for WPRT in the years to come: https://www.thedailybeast.com/diesel-trains-may-soon-use-natural-gas-instead.
Go $WPRT!
That's what I'm talking about wolf!
Nice i bought 30 $4 dollar November calls this morning as well as 30 $4 December as well! Should be looking pretty green tomorrow!
Read the article dude.
No worries, we will be rolling in it by 2025.......LOL And sooner than that....
Just another report but again,"The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include USCOME LTD, Abbott Laboratories, Inc., BIOHEART, INC., BIOSENSORS INTERNATIONAL GROUP, BIOTRONIK SE & CO. KG, Boston Scientific Corporation, CARDIOROBOTICS, INC., Cook Medical Inc., GE HEALTHCARE, MEDICO S.p.A., Medtronic Company, SORIN Group, St. Jude Medical, Inc., Vitatron, Zoll Medical Corporation, Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments."
Where do you guys project PPS for this stock. See quite a few established members on this board.
bought in for 2 million shares today at.00055 average.
https://morganleader.com/share-performance-update-on-u-s-stem-cell-inc-usrm/
https://bentonbulletin.com/stock-check-viewing-levels-for-u-s-stem-cell-inc-usrm/265284/
50 day EMA gives recent price action the most weight. 50 day is at 0.0261 that's our next level of support however as the articles state we are in oversold territory in the context of a strong upward trend.
Wait for it......
well I guess they just fixed that. lol
The bid is filling up at 29 and 27.....looking good.
Love it!
Funny, Myo Cath is still on their web site and every other forum so I will just have to believe either you are wrong or there are other things going on behind the scenes. Have a feeling the price will tell us soon enough......
Old post from MyStreet bears repeating:
Yeah pretty sure Myocath was approved by FDA in 2009.
Here is some additional info on Myocath:
Myocath info:
http://www.prnewswire.com/news-releases/bioheart-announces-cell-therapies-program-in-latin-america-for-congestive-heart-failure-and-peripheral-arterial-disease-patients-88949077.html
The MyoCath was developed by Bioheart co-founder Robert Lashinski specifically for delivering new cells to damaged tissue. It is a deflecting tip needle injection catheter that has a larger needle which is 25 gauge for better flow rates and less leakage than systems that are 27 gauge. This larger needle allows for thicker compositions to be injected which helps with cell retention in the heart. Also, the MyoCath needle has more fluoroscopic brightness than the normally used nitinol needle, enabling superior visualization during the procedure. Seeing the needle well during injections enables the physician who is operating the catheter to pinpoint targeted areas more precisely, thus improving safety. The MyoCath competes well with other biological delivery systems on price and efficiency and allows the physician to utilize standard fluoroscopy and echo equipment found in every cath lab.
Howard Leonhardt, Bioheart's Founder and Chief Scientific and Technology Officer, assessing the MyoCath's use in clinical trials stated: "The MyoCath was the primary catheter utilized in Bioheart's Phase I study for the US FDA completed at the Mayo Clinic, Minneapolis Heart Institute, Atlanta Cardiovascular Research Institute and Columbia University Medical Center. It was also the primary catheter used in Bioheart's Phase II study led by Professor Patrick Serruys in Europe. Physicians feel that the MyoCath provides superior flexibility along with precision when compared to the alternatives."
Stuart K. Williams, Ph.D., of the University of Louisville and Chief Scientific Officer of Tissue Genesis, Inc., commenting on the MyoCath: "The MyoCath brings an incredible amount of technology to the delivery of cells through an intravascular route to the damaged area of the heart. This is not a trivial problem, and I am impressed with Bioheart's technology in this field. The major attribute of the MyoCath technology is its simple design and implementation. I have seen some incredibly complex technology necessitating a long learning curve before utilization, resulting in significant potential problems. It's all about placement, reproducibility and precision. The MyoCath development team has done a fantastic job."
Producers and prime Sellers of world Myocardial Revascularization, Repair, and Regeneration Products and Therapies Market 2017:
Medtronic, Inc.
Covidien
Abbott Laboratories
Advanced Cell Technology, Inc.
Bioheart, Inc.
BIOTRONIK GmbH & Company KG
Boston Scientific Corporation
B. Braun Melsungen AG
Cardica, Inc
http://editionanalyst.com/global-myocardial-revascularization-repair-and-regeneration-products-and-therapies-market-2017-covidien-bioheart-cardica-medtronic/
https://www.healthcarepackaging.com/article/applications/healthcare/fda-moves-forward-breakthrough-med-device-development
Buy the report if you need to. I can read between the lines.
That happens on every stock, not sure how or why. I think maybe institutional???? I'd like to know too.
HERE, HERE!!!!!!!
What I am saying my friend is that this thing ran up from 0.0197 to .04 in less than two weeks! 13 days to be exact, that's like 200 percent bro, even though with my average it was 70% for me, that was a 200% F$%^&ing run.
It was a mistake to think that we didn't have a correction coming and I am guilty too, I love this company! Now if this thing goes on to new lows and the trend just completely breaks down then we can talk about gross manipulation; but you're not going to get new longs jumping into an overbought stock. IMHO
I agree with you, however moving averages play a part in all of this as they are daily support and resistance along with your pivots.
The way the chart looks now we either come back over the .0301 -.0308 which is where resistance lies right now in the form of the nine and the twenty. below us we have support at the 50 which is sitting at 0.0261. That number will be a little higher Monday if we hold this level today.
All of this looks very healthy to me so far. We have major risistance in the fours and without news you're not going to see a bullish run through the 200 day MA over night. If you do buy more cause someone knows something we don't.
FYI: The last run put us into overbought territory. It was natural for the price to come down, to correct. We can only ask for higher highs and higher lows, and at this point it could drop to 0.0262 and still be in bullish territory. Have no fear, know what you own, and buy on every dip............Go USRM!
Oh, and we are now in oversold territory so we should expect a different looking chart next week. Well, let's hope!
https://www.healthcarepackaging.com/article/applications/healthcare/fda-moves-forward-breakthrough-med-device-development
Here is a nice quote from the FDA, "Qualification of a medical device development tool (MDDT), with the goal of providing “a more objective platform for developing devices in a key area of medicine – cardiovascular health.”
If you didn't know USRM, AKA Bioheart is involved in manufacturing devices in this key area of medicine and is expected to reap benefits from their Diagnostic Electrophysiology Catheter's AKA: MYOCATH as well as other medical devices.
It means a little something.
Yes, during the day you have the flippers doing there thing, and stop orders kick in as others take profits, however you didn't see eight and up on the level two a month or so ago.
It also tells me something about where the mm's think this thing is going IMO (could be wrong about that). We do have a gap to cover from eight and therefore I'm led to believe that my above statement is correct.
As Eltp said, "Eventually"